SUNFISH Pivotal Results for Risdiplam (RG7916) Demonstrate Medically Meaningful Benefit in Broadest Age Group of Patients Studied with Type 2 and 3 Spinal Muscular Atrophy

Corporate Breaking News

Home : SUNFISH Pivotal Results for Risdiplam (RG7916) Demonstrate Medically Meaningful Benefit in Broadest Age Group of Patients Studied with Type 2 and 3 Spinal Muscular Atrophy

Feb 06 2020	SUNFISH Pivotal Results for Risdiplam (RG7916) Demonstrate Medically Meaningful Benefit in Broadest Age Group of Patients Studied with Type 2 and 3 Spinal Muscular Atrophy
SOUTH PLAINFIELD, N.J., Feb. 6, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that positive 1 year clinical data from Part 2 of the pivotal SUNFISH study evaluating risdiplam in people aged 2-25 years with nonambulatory type 2 and type 3 spinal muscular...


Source:https://www.prnewswire.com:443/news-releases/sunfish-pivotal-results-for-risdiplam-rg7916-demonstrate-medically-meaningful-benefit-in-broadest-age-group-of-patients-studied-with-type-2-and-3-spinal-muscular-atrophy-300999908.html

Related News
» Cardiac Ablation Market Revenue to Cross US$ 6.5 Bn by 2026: Global Market Insights, Inc. » Dutypoint Releases Revolutionary New Packaged Pumping Station That Reduces Labour Hours by 35% and Concrete Usage by up to 50%